MNPR · Monopar Therapeutics · Proposed Sales

$71.42 +4.20 (+6.25%) At close · Nov 6

Russell 2000 member Rebalance outlook locked

Market Cap

$479.38M

6.71M

Volume · Nov 6 94.21K Avg daily vol (3M) 164.19K

Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.

Filed	Seller	Relationship	Shares	Market Value	Approx. Sale	Broker
2026-10-01	CHRISTOPHER STARR	Director	16,800	$1,338,456	2026-10-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-09-24	CHANDLER ROBINSON	Director, Officer	29,056	$2,597,025	2026-09-24	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-08-26	PATRICE RIOUX	Acting Chief Medical Officer	1	$111	2026-08-26	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-08-26	KIM TSUCHIMOTO	Director	8,180	$906,508	2026-08-26	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-08-25	RAYMOND WILLIAM ANDERSON	Director	6,284	$699,786	2026-08-25	Morgan Stanley Smith Barney LLC Executive Financial Services
2025-12-19	Arthur Klausner	Board Member	5,121	$343,903	2025-12-18	MLPFS
2025-07-14	Robinson Chandler	Officer, Director	16,800	$672,000	2025-07-14	Merrill Lynch Pierce Fenner & Smith Inc.
2025-07-14	Tsuchimoto Kim R	Director	8,904	$356,160	2025-07-14	Merrill Lynch Pierce Fenner & Smith Inc.
2025-07-14	STARR CHRISTOPHER M	Director	16,800	$672,000	2025-07-14	Merrill Lynch Pierce Fenner & Smith Inc.
2025-04-02	Tactic Pharma LLC	10% Stockholder	33,334	$1,166,806	2025-04-02	Merrill Lynch, Pierce, Fenner & Smith, Inc.

Showing 1–10 of 10 filings

Key facts CIK 1645469 CUSIP 61023L207 13F (30d) 28 filings 24 filers Visit website Investor relations